Health Care • Biotechnology: Laboratory Analytical Instruments
$16.05 ▼ -0.63
(-3.78%)
MKT CAP: $11.30B • VOL: 9.73M
52W L $7 52W H $17
AVTR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.55B | $6.78B | $6.97B |
| YoY Revenue Growth % | -3.4% | -2.6% | — |
| Gross Profit | $2.14B | $2.28B | — |
| Gross Margin % | 32.7% | 33.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$246.2M | $1.08B | $696.4M |
| Operating Margin % | -3.8% | 16.0% | 10.0% |
| Net Income (GAAP) | -$530.2M | $711.5M | $321.1M |
| EBITDA (Normalized) | -$143.2M | $1.20B | $947.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $623.8M | $840.8M | $870.0M |
| Capital Expenditures (CapEx) | $128.8M | $148.8M | $313.5M |
| Free Cash Flow (FCF) | $495.0M | $692.0M | $556.5M |
| FCF Margin % | 7.6% | 10.2% | 8.0% |
| Return on Invested Capital (ROIC %) | -2.1% | 9.6% | 10.9% |
| Cash & Short-Term Equivalents | $365.4M | $261.9M | — |
| Total Debt (Short + Long Term) | $3.92B | $3.23B | $1.96B |
| Total Stockholders' Equity | $5.57B | $5.96B | $4.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AVTR.